COVID-19 Risk Hematologic Malignancies

Here are the ⁤relevant⁣ facts from the provided text:

High ⁤Risk Continues: Even as COVID-19 transitioned to an endemic disease,people with⁤ hematologic malignancies remained at high risk of ‍serious illness and death from the‍ infection.
Study Publication: A new study detailing these findings was published in Cancer ‍Medicine.
Vaccination Doesn’t ‍Eliminate Risk: critical ⁣illness with SARS-CoV-2 ⁣infection⁢ was common even among vaccinated patients⁢ with hematologic malignancies.
Increased Vulnerability: People with hematologic‍ cancers were found to be more vulnerable to COVID-19 than those with solid ⁢tumors.
Case Fatality Rate: A June 2021 study showed a ‍14.9% case fatality rate among those‍ with⁤ hematologic malignancies diagnosed with COVID-19, compared to 4.8% among those with solid tumors.
Vaccine Debate: There’s ongoing debate regarding the safety and efficacy of COVID-19 vaccines⁢ in immunocompromised patients.
study Focus: Most research on COVID-19 in this patient population occurred in the first 2 years of the pandemic, highlighting the need for‍ analysis of later phases.
Study Details: the current study was a single-centre observational study conducted⁢ at the University ⁤Hospital ⁣Renato Dulbecco in Catanzaro.
Study Period: COVID-19 cases included ⁢in the study were diagnosed between January 1, 2022, and December 31,‍ 2023.
Patient count: A total ⁣of 85 patients were included in the⁤ study.
*⁢ Common Malignancies: the⁣ most common hematologic malignancies among the study participants were multiple myeloma (33 patients) and non-Hodgkin lymphoma (30 patients). Nine patients had chronic lymphocytic leukemia.